Renaissance Technologies LLC grew its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 516.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 579,562 shares of the biopharmaceutical company’s stock after buying an additional 485,600 shares during the period. Renaissance Technologies LLC owned approximately 0.54% of Regeneron Pharmaceuticals worth $217,892,000 at the end of the most recent quarter.
Several other hedge funds have also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC lifted its position in Regeneron Pharmaceuticals by 495.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $138,000 after acquiring an additional 307 shares in the last quarter. Advisory Services Network LLC lifted its position in Regeneron Pharmaceuticals by 147.0% during the 4th quarter. Advisory Services Network LLC now owns 447 shares of the biopharmaceutical company’s stock worth $168,000 after buying an additional 266 shares in the last quarter. Vident Investment Advisory LLC bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $200,000. Moors & Cabot Inc. bought a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth about $217,000. Finally, Mackenzie Financial Corp bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth about $204,000. 66.40% of the stock is owned by institutional investors.
Shares of Regeneron Pharmaceuticals Inc (REGN) traded up $3.67 during trading hours on Wednesday, reaching $341.42. 578,148 shares of the company traded hands, compared to its average volume of 1,120,000. The company has a current ratio of 3.82, a quick ratio of 3.18 and a debt-to-equity ratio of 0.11. Regeneron Pharmaceuticals Inc has a 12 month low of $313.53 and a 12 month high of $543.55. The stock has a market capitalization of $36,680.00, a PE ratio of 25.98, a P/E/G ratio of 1.08 and a beta of 1.54.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. The business had revenue of $1.58 billion during the quarter, compared to analysts’ expectations of $1.50 billion. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The business’s quarterly revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.04 EPS. equities analysts anticipate that Regeneron Pharmaceuticals Inc will post 19.2 earnings per share for the current year.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the company’s stock in a transaction on Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction on Wednesday, March 14th. The shares were sold at an average price of $340.00, for a total transaction of $680,000.00. Following the sale, the director now owns 14,000 shares of the company’s stock, valued at $4,760,000. The disclosure for this sale can be found here. Insiders own 10.80% of the company’s stock.
A number of brokerages have recently issued reports on REGN. Zacks Investment Research raised shares of Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th. BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 26th. Royal Bank of Canada restated a “hold” rating and set a $430.00 target price on shares of Regeneron Pharmaceuticals in a research report on Thursday, December 14th. Evercore ISI decreased their target price on shares of Regeneron Pharmaceuticals from $605.00 to $445.00 and set an “outperform” rating on the stock in a research report on Thursday, November 16th. Finally, BTIG Research reiterated a “buy” rating and set a $520.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. Regeneron Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $449.49.
TRADEMARK VIOLATION WARNING: This story was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://ledgergazette.com/2018/03/15/renaissance-technologies-llc-has-217-89-million-holdings-in-regeneron-pharmaceuticals-inc-regn.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.